Shire Says Key Data on HAE Drug Bodes Well for U.S. Approval Shire Says Key Data on HAE Drug Bodes Well for U.S. Approval

Shire Plc said successful late-stage data on its long-acting drug for hereditary angioedema would form the basis of a U.S. marketing application for the treatment.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news